论文部分内容阅读
目的:对比研究醒脑静与尼可刹米分别联合无创正压机械通气(NIPPV)治疗呼吸衰竭并肺性脑病的临床疗效。方法:随机将84例COPD呼吸衰竭合并肺性脑病轻中型患者分为醒脑静联合无创正压机械通气治疗组(治疗组)与尼可刹米联合NIPPV治疗组(对照组);2组均在NIPPV基础上予平喘、祛痰、抗感染等治疗,治疗组加用醒脑静,对照组加用尼可刹米。结果:治疗组与对照组格拉斯哥评分、血气分析、机械通气时间、气管插管率的结果比较,经统计学处理,差异有显著性(P<0.05)。结论:本观察证明醒脑静联合NIPPV治疗COPD呼吸衰竭合并肺性脑病较尼可刹米联合NIPPV治疗COPD呼吸衰竭合并肺性脑病临床疗效更佳。
Objective: To compare the clinical effects of xingnaojing and nikethamide combined with non-invasive positive pressure mechanical ventilation (NIPPV) in the treatment of respiratory failure and pulmonary encephalopathy. Methods: Eighty-four patients with COPD with pulmonary encephalopathy were randomly divided into Xingnaojing combined with noninvasive positive pressure mechanical ventilation group (treatment group) and nikethamide combined with NIPPV treatment group (control group) On the basis of NIPPV to asthma, expectorant, anti-infective treatment, the treatment group plus Xingnaojing, the control group with niccaseham. Results: The results of Glasgow score, blood gas analysis, mechanical ventilation time and tracheal intubation rate in the treatment group and the control group were statistically significant (P <0.05). Conclusion: This observation shows that xingnaojing combined with NIPPV for COPD respiratory failure combined with pulmonary encephalopathy is more effective than nikkakemide combined with NIPPV in treating COPD respiratory failure with pulmonary encephalopathy.